WASHINGTON, Nov. 22 /PRNewswire-FirstCall/ -- Danaher Corporation announced today that the offer period for its tender offer to acquire all of the shares of Vision Systems Limited has been extended and is now scheduled to close at 7:00pm (Melbourne time) on December 8, 2006. As previously announced, the offer is unconditional and payment is dispatched to accepting shareholders within 5 business days after the shares are tendered. Danaher currently owns approximately 63.6% of the outstanding Vision shares.
Founded in 1987 and headquartered in Melbourne, Australia, Vision has operations in Australia, the United States and the United Kingdom. Vision is a manufacturer and marketer of automated instruments including the Peloris(TM) rapid tissue processor and the Bond(TM)-maX advanced staining system, as well as Novocastra(TM) antibodies and biochemical reagents for biopsy-based detection of cancer and infectious diseases.
Danaher Corporation is a leading manufacturer of Professional Instrumentation, Industrial Technologies, and Tools and Components (http://www.danaher.com/).
Statements in this release that are not strictly historical may be "forward-looking" statements. These forward-looking statements include statements about the offer, Danaher's acquisition of shares under the offer and any other statements about future expectations, beliefs, goals, plans or prospects. There are a number of important risks and uncertainties that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements. These risks and uncertainties include, among other things, the competitive nature of acquisitions, acceptance of the offer by Vision's shareholders and noteholders, regulatory approvals and potential changes in the environment for making acquisitions and divestitures, including changes in the market value of acquisition candidates, general economic conditions as well as other risks and uncertainties set forth in Danaher's filings with the United States Securities and Exchange Commission. These forward-looking statements speak only as of the date of this release and Danaher does not intend to update any forward-looking statement.
